Janumet 50 mg/500 mg Tablets contain a combination of Sitagliptin (50 mg) and Metformin Hydrochloride (500 mg), two oral antihyperglycemic agents used to manage type 2 diabetes mellitus. Sitagliptin is a DPP-4 inhibitor that increases incretin levels to stimulate insulin secretion and reduce glucagon levels. Metformin is a biguanide that lowers glucose production in the liver and improves insulin sensitivity. This formulation is typically used when blood sugar is not adequately controlled with Metformin alone.

• Provides synergistic control of blood sugar levels

• Improves both fasting and postprandial glucose readings

• Helps reduce HbA1c effectively

• May delay disease progression and complications

• Weight-neutral with low risk of hypoglycemia

• Take one tablet twice daily, preferably with meals to minimize gastrointestinal side effects

• Swallow the tablet whole with water

• Use consistently at the same times each day

• Usual starting dose: 50 mg Sitagliptin / 500 mg Metformin twice daily

• Dose may be increased gradually depending on glycemic response and tolerability

• Not suitable for patients with significantly impaired kidney function

• Not intended for use in type 1 diabetes or diabetic ketoacidosis

• Kidney function must be monitored regularly

• Use with caution in elderly patients and those at risk of dehydration

• Discuss use during pregnancy or breastfeeding with a healthcare provider

• Common side effects:

• Nausea

• Diarrhea

• Rare but serious side effects:

• Lactic acidosis (especially in those with kidney or liver dysfunction)

• Pancreatitis

• Vitamin B12 deficiency with long-term use

• Hypoglycemia when used with insulin or sulfonylureas

•  

• Headache

• Mild abdominal discomfort